TY - JOUR
T1 - Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation
T2 - Post hoc analysis of the L-arginine trial
AU - Monti, Lucilla D.
AU - Galluccio, Elena
AU - Fontana, Barbara
AU - Spadoni, Serena
AU - Comola, Mauro
AU - Marrocco Trischitta, Massimiliano M.
AU - Chiesa, Roberto
AU - Comi, Giancarlo
AU - Bosi, Emanuele
AU - Piatti, Piermarco
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Objective To evaluate whether variants of the eNOS gene are associated with endothelial and metabolic responses to L-arginine (L-arg) supplementation. Material and Methods We examined a single nucleotide polymorphism of the eNOS gene (rs753482-A > C) to investigate the effects of this variant on endothelial function (EF), colony-forming unit-endothelial cell (CFU-EC) number, asymmetric-dimethylarginine (ADMA) level, insulin sensitivity index (ISI), and insulin secretion (IS) in a post hoc analysis of the L-arg trial. The L-arg trial (6.4 g/day for 18 months) was a single-center, randomized, double-blind, parallel-group, placebo-controlled, phase III trial in individuals with impaired glucose tolerance and metabolic syndrome. followed by a 12-month extended follow-up period after termination of the study drug (NCT 00917449). Results At baseline, EF, CFU-EC numbers, ADMA levels, and ISI were impaired in subjects carrying minor allele C (both heterozygotes, AC and homozygotes, CC) as compared to subjects carrying major allele A (homozygotes, AA) (p <0.01). Compared to placebo, L-arg increased EF, CFU-EC numbers, and ISI, and improved ADMA levels and IS (p <0.01). The greatest improvements were found in AA subjects treated with L-arg, while the worst results were found in AC + CC subjects treated with placebo. In the placebo-treated subjects, EF, CFU-EC, ISI, and IS were significantly lower and ADMA was significantly higher in AC + CC subjects than in AA subjects. Conclusions Treatment with L-arg induced similar improvements in EF, CFU-EC numbers, ADMA levels, ISI, and IS in both AA subjects and AC + CC subjects. The presence of minor allele resulted in the worst prognosis in terms of EF, CFU-EC numbers, ADMA levels, ISI, and IS during the 30-month observation period.
AB - Objective To evaluate whether variants of the eNOS gene are associated with endothelial and metabolic responses to L-arginine (L-arg) supplementation. Material and Methods We examined a single nucleotide polymorphism of the eNOS gene (rs753482-A > C) to investigate the effects of this variant on endothelial function (EF), colony-forming unit-endothelial cell (CFU-EC) number, asymmetric-dimethylarginine (ADMA) level, insulin sensitivity index (ISI), and insulin secretion (IS) in a post hoc analysis of the L-arg trial. The L-arg trial (6.4 g/day for 18 months) was a single-center, randomized, double-blind, parallel-group, placebo-controlled, phase III trial in individuals with impaired glucose tolerance and metabolic syndrome. followed by a 12-month extended follow-up period after termination of the study drug (NCT 00917449). Results At baseline, EF, CFU-EC numbers, ADMA levels, and ISI were impaired in subjects carrying minor allele C (both heterozygotes, AC and homozygotes, CC) as compared to subjects carrying major allele A (homozygotes, AA) (p <0.01). Compared to placebo, L-arg increased EF, CFU-EC numbers, and ISI, and improved ADMA levels and IS (p <0.01). The greatest improvements were found in AA subjects treated with L-arg, while the worst results were found in AC + CC subjects treated with placebo. In the placebo-treated subjects, EF, CFU-EC, ISI, and IS were significantly lower and ADMA was significantly higher in AC + CC subjects than in AA subjects. Conclusions Treatment with L-arg induced similar improvements in EF, CFU-EC numbers, ADMA levels, ISI, and IS in both AA subjects and AC + CC subjects. The presence of minor allele resulted in the worst prognosis in terms of EF, CFU-EC numbers, ADMA levels, ISI, and IS during the 30-month observation period.
KW - eNOS polymorphism
KW - Insulin Secretion
KW - Insulin Sensitivity
KW - L-Arginine
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=84944441465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944441465&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2015.08.015
DO - 10.1016/j.metabol.2015.08.015
M3 - Article
C2 - 26385052
AN - SCOPUS:84944441465
VL - 64
SP - 1582
EP - 1591
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 11
ER -